Overview Efficacy and Tolerability of Angeliq in Thai Women Status: Completed Trial end date: 2006-12-01 Target enrollment: Participant gender: Summary To evaluate the safety, tolerability, and efficacy of Angeliq in Thai post menopausal women with hot flushes and other climacteric symptoms. Phase: Phase 4 Details Lead Sponsor: BayerTreatments: Drospirenone and ethinyl estradiol combinationEstradiolEstradiol 17 beta-cypionateEstradiol 3-benzoateEstradiol valeratePolyestradiol phosphate